|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 7 (October 1), 1998:
pp. 2477-2483
Analysis of Major Histocompatibility Complex Class I, TAP
Expression, and LMP2 Epitope Sequence in Epstein-Barr
Virus-Positive Hodgkin's Disease
Paul G. Murray,
Christothea M. Constandinou,
John Crocker,
Lawrence S. Young, and
Richard F. Ambinder
From the CRC Institute for Cancer Studies, University of Birmingham,
Edgbaston, Birmingham; the School of Health Sciences, University of
Wolverhampton, Wolverhampton; the Department of Histopathology,
Birmingham Heartland Hospital, Birmingham, UK; and Johns Hopkins
Oncology Center, Baltimore, MD.
The Epstein-Barr virus (EBV)-encoded latent membrane proteins, LMP1
and LMP2, are consistently expressed by the malignant Hodgkin/Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease
(HD). Cytotoxic T lymphocyte (CTL) responses to both of these proteins
have been shown in the blood of EBV-seropositive individuals, yet in HD
the apparent failure of the CTL response to eliminate HRS cells
expressing LMP1 and LMP2 in vivo has given rise to the suggestion that
HD may be characterized by the presence of defects in antigen
processing/presentation or in CTL function. This study has used
immunohistochemistry to show high-level expression of major
histocompatibility complex (MHC) class I molecules by the HRS cells of
EBV-associated HD and either low level or absence of expression of MHC
class I molecules on HRS cells of EBV-negative tumors. In addition, HRS
cells expressed high levels of transporter-associated proteins (TAP-1,
-2), irrespective of the presence of latent EBV infection. These
results suggest that global downregulation of MHC class I molecules
does not account for the apparent ability of EBV-infected HRS cells to
evade CTL responses, but may be important in the understanding of
EBV-negative disease.We have also sequenced an epitope in LMP2A
(CLGGLLTMV) that is restricted through HLA A2.1, a relatively
common allele in Caucasian populations, and showed that
this epitope is wild type in a small group of EBV-associated HLA
A2.1-positive HD tumors. This result may be relevant to proposed immunotherapeutic approaches for EBV-positive HD patients that target
CTL epitopes.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Diepstra, G. W. van Imhoff, M. Schaapveld, H. Karim-Kos, A. van den Berg, E. Vellenga, and S. Poppema
Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin's Lymphoma Predicts Adverse Outcome in Older Adult Patients
J. Clin. Oncol.,
August 10, 2009;
27(23):
3815 - 3821.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Weng, S. Lu, M. Zhong, Z. Liang, G. Shen, J. Chen, and X. Wu
Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein
J. Leukoc. Biol.,
March 1, 2009;
85(3):
574 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Kapatai and P Murray
Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1342 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Niens, R. F. Jarrett, B. Hepkema, I. M. Nolte, A. Diepstra, M. Platteel, N. Kouprie, C. P. Delury, A. Gallagher, L. Visser, et al.
HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma
Blood,
November 1, 2007;
110(9):
3310 - 3315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Bollard, S. Gottschalk, A. M. Leen, H. Weiss, K. C. Straathof, G. Carrum, M. Khalil, M.-f. Wu, M. H. Huls, C.-C. Chang, et al.
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
Blood,
October 15, 2007;
110(8):
2838 - 2845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Diepstra, G. W. van Imhoff, H. E. Karim-Kos, A. van den Berg, G. J. te Meerman, M. Niens, I. M. Nolte, E. Bastiaannet, M. Schaapveld, E. Vellenga, et al.
HLA Class II Expression by Hodgkin Reed-Sternberg Cells Is an Independent Prognostic Factor in Classical Hodgkin's Lymphoma
J. Clin. Oncol.,
July 20, 2007;
25(21):
3101 - 3108.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Niens, A. van den Berg, A. Diepstra, I. M. Nolte, G. van der Steege, A. Gallagher, G. M. Taylor, R. F. Jarrett, S. Poppema, and G. J. te Meerman
The Human Leukocyte Antigen Class I Region Is Associated with EBV-Positive Hodgkin's Lymphoma: HLA-A and HLA Complex Group 9 Are Putative Candidate Genes.
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2006;
15(11):
2280 - 2284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H.M. Keegan, S. L. Glaser, C. A. Clarke, R. F. Dorfman, R. B. Mann, J. A. DiGiuseppe, E. T. Chang, and R. F. Ambinder
Body Size, Physical Activity, and Risk of Hodgkin's Lymphoma in Women.
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2006;
15(6):
1095 - 1101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H.M. Keegan, S. L. Glaser, C. A. Clarke, M. L. Gulley, F. E. Craig, J. A. DiGiuseppe, R. F. Dorfman, R. B. Mann, and R. F. Ambinder
Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based Study
J. Clin. Oncol.,
October 20, 2005;
23(30):
7604 - 7613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Setiadi, M. D. David, S. S. Chen, J. Hiscott, and W. A. Jefferies
Identification of Mechanisms Underlying Transporter Associated with Antigen Processing Deficiency in Metastatic Murine Carcinomas
Cancer Res.,
August 15, 2005;
65(16):
7485 - 7492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Demanet, A. Mulder, V. Deneys, M. J. Worsham, P. Maes, F. H. Claas, and S. Ferrone
Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack?
Blood,
April 15, 2004;
103(8):
3122 - 3130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Edwards, D. Sitki-Green, D. T. Moore, and N. Raab-Traub
Potential Selection of LMP1 Variants in Nasopharyngeal Carcinoma
J. Virol.,
January 15, 2004;
78(2):
868 - 881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Meyer, R. F. Ambinder, and S. Stroobants
Hodgkin's Lymphoma: Evolving Concepts with Implications for Practice
Hematology,
January 1, 2004;
2004(1):
184 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Ambinder
Infection and Lymphoma
N. Engl. J. Med.,
October 2, 2003;
349(14):
1309 - 1311.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J J Oudejans, R L ten Berge, and C J L M Meijer
Immune escape mechanisms in ALCL
J. Clin. Pathol.,
June 1, 2003;
56(6):
423 - 425.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.-W. Ong, A. D. Wilson, T. R. Hirst, and A. J. Morgan
The B Subunit of Escherichia coli Heat-Labile Enterotoxin Enhances CD8+ Cytotoxic-T-Lymphocyte Killing of Epstein-Barr Virus-Infected Cell Lines
J. Virol.,
April 1, 2003;
77(7):
4298 - 4305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. N. Chapman, A. B. Rickinson, W. A. Thomas, R. F. Jarrett, J. Crocker, and S. P. Lee
Epstein-Barr Virus-specific Cytotoxic T Lymphocyte Responses in the Blood and Tumor Site of Hodgkin's Disease Patients: Implications for a T-cell-based Therapy
Cancer Res.,
August 1, 2001;
61(16):
6219 - 6226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K J Flavell and P G Murray
Hodgkin's disease and the Epstein-Barr virus
Mol. Pathol.,
October 1, 2000;
53(5):
262 - 269.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Willenbrock, A. Roers, B. Blohbaum, K. Rajewsky, and M.-L. Hansmann
CD8+ T Cells in Hodgkin's Disease Tumor Tissue Are a Polyclonal Population with Limited Clonal Expansion but Little Evidence of Selection by Antigen
Am. J. Pathol.,
July 1, 2000;
157(1):
171 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Chambost, N. Van Baren, F. Brasseur, D. Godelaine, L. Xerri, S. J. Landi, I. Theate, J. Plumas, G. C. Spagnoli, G. Michel, et al.
Expression of gene MAGE-A4 in Reed-Sternberg cells
Blood,
June 1, 2000;
95(11):
3530 - 3533.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Xu, A. Ahmad, M. D'Addario, L. Knafo, J. F. Jones, U. Prasad, R. Dolcetti, E. Vaccher, and J. Menezes
Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated Diseases
J. Immunol.,
March 1, 2000;
164(5):
2815 - 2822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Caldwell, R. C. Brown, and R. Longnecker
Epstein-Barr Virus LMP2A-Induced B-Cell Survival in Two Unique Classes of E{micro}LMP2A Transgenic Mice
J. Virol.,
February 1, 2000;
74(3):
1101 - 1113.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Franchini, R. F. Ambinder, and M. Barry
Viral Disease in Hematology
Hematology,
January 1, 2000;
2000(1):
409 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Yang, V. M. Lemas, I. W. Flinn, C. Krone, and R. F. Ambinder
Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens
Blood,
January 1, 2000;
95(1):
241 - 248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Kim, Y. K. Shin, I.-s. Lee, Y. M. Bae, H. W. Sohn, Y. H. Suh, H. J. Ree, M. Rowe, and S. H. Park
Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype
Blood,
January 1, 2000;
95(1):
294 - 300.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Chu, K. L. Chang, W.-G. Chen, Y.-Y. Chen, D. Shibata, K. Hayashi, C. Bacchi, M. Bacchi, and L. M. Weiss
Epstein-Barr Virus (EBV) Nuclear Antigen (EBNA)-4 Mutation in EBV-Associated Malignancies in Three Different Populations
Am. J. Pathol.,
September 1, 1999;
155(3):
941 - 947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Murray, L. J. Billingham, H. T. Hassan, J. R. Flavell, P. N. Nelson, K. Scott, G. Reynolds, C. M. Constandinou, D. J. Kerr, E. C. Devey, et al.
Effect of Epstein-Barr Virus Infection on Response to Chemotherapy and Survival in Hodgkin's Disease
Blood,
July 15, 1999;
94(2):
442 - 447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
